ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
ZEVRA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.16+0.22 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $623.18M
- P/E (TTM)
- 10.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
84.5%
Operating margin
-59.1%−16.9 pts over 5 years
Net margin
78.2%+174.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +350.9% | +118.8% | +51.6% | – | |
| Gross profit | +455.7% | +108.4% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 114.6% | 18.1% | 85.7% | |
| Return on assets | -23.7% | -117.5% | 36.0% | |
| Current ratio | 11.19 | 1.11 | 5.68 | |
| Debt to equity | – | – | 0.40 | |
| Net debt to EBITDA | – | – | 0.01× | |
| Interest coverage | -6.8× | -1.2× | -7.9× | |
| Inventory turnover | – | – | 8.9× | |
| Capex to revenue | – | 0.2% | 0.8% | |
| Diluted shares | 1M | 4M | 57M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Zevra Therapeutics generated $133.95M from operations and spent $12.31M on capital expenditure, dividends and share buybacks. 11% of that went back into the business.
Generated
$133.95M
Used
$12.31M
Capital expenditure$1.33M11%Dividends$00%Share buybacks$10.98M89%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin78.2%
×Asset turnover0.46×
×Equity multiplier2.38×
=Return on equity, FY202585.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 78.2% | 0.46× | 2.38× | 85.7% |
| FY2024 | -446.9% | 0.13× | 3.45× | -207.8% |
| FY2023 | -167.7% | 0.19× | 2.10× | -67.2% |
| FY2022 | -263.5% | 0.08× | 1.40× | -30.3% |
| FY2021 | -29.9% | 0.40× | 4.09× | -48.5% |
| FY2020 | -96.0% | 1.22× | -0.15× | 18.1% |
| FY2019 | -191.0% | 0.69× | -0.26× | 34.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$83.23M
- Cash generatingOperating cash flow above zero-$1.60M
- Return on assets improvedROA up on the prior year-61.2% → 46.7%
- Earnings backed by cashOperating cash flow above net income-$1.60M vs $83.23M
- Less leverageLong-term debt to assets fell33.4% → 21.7%
- Better liquidityCurrent ratio rose2.53 → 5.68
- No dilutionShare count did not rise46M → 57M
- Gross margin improvedGross margin up on the prior year68.59% → 84.52%
- More efficientAsset turnover rose0.14 → 0.60